This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Can Hims Recover after Novo Nordisk Diss?
by David Bartosiak
Hims shares tumbled after Novo Nordisk canceled its partnership. Can the stock recover?
Hims & Hers Strengthens Its Footprint in Consumer-Driven Obesity Care
by Debanjana Dey
HIMS expands its weight loss platform with a bundled Wegovy program and tech-driven obesity care solutions.
Can Novo Nordisk Regain Ground After Cutting Ties With Hims & Hers?
by Ahan Chakraborty
NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.
Zacks Investment Ideas feature highlights: Nasdaq 100 Index ETF, US Oil Fund ETF, Advanced Micro Devices, Tesla and Hims and Hers Health
by Zacks Equity Research
Markets rebound as QQQ holds key levels, oil fades post-Iran strike, and AMD, TSLA, and HIMS deliver headline-making moves.
Should You Continue to Retain Abbott Stock in Your Portfolio Now?
by Zacks Equity Research
ABT rides on strong global demand in diagnostics and diabetes care, but macro headwinds may test its momentum ahead.
Is This the Right Time to Hold EYE Stock in Your Portfolio?
by Zacks Equity Research
National Vision gains from America's Best momentum and strategic revamp, but solvency issues and rising costs weigh on profitability.
Hims & Hers Health, Inc. (HIMS) Stock Declines While Market Improves: Some Information for Investors
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $41.98, signifying a -34.63% move from its prior day's close.
HIMS Stock Crashes 30% in a Day: Time to Buy the Dip?
by Ethan Feller
Hims & Hers stock crashes 30% on Monday after news of Novo Nordisk ending their partnership. Is HIMS now a compelling stock to buy?
Bulls Shrug Off Iran Strikes, Recover from Initial Oil Jolt
by Andrew Rocco
Price action is the best 'tell' that exists on Wall Street. The resilient price action in the stock market suggests that geopolitical fears are likely overdone.
TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +
by Zacks Equity Research
Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.
Hims & Hers Stock Jumps 85.1% in 3 Months: Is It a Buy Now?
by Debanjana Dey
HIMS accelerates global growth with ZAVA deal, AI investments and expanded access to obesity care treatments. However, macro challenges may hurt performance.
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
by Zacks Equity Research
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?
by Zacks Equity Research
Abbott gains Health Canada approval for its i-STAT TBI test, enabling rapid bedside concussion detection via whole blood.
Should You Add NVST Stock to Your Portfolio Right Now?
by Zacks Equity Research
Envista's global expansion, smart acquisitions, and strong balance sheet support growth but forex risks remain a drag.
Reasons to Add PAHC Stock to Your Portfolio Right Now
by Zacks Equity Research
Phibro's strong Animal Health momentum and global expansion bode well for investors.
Bet on Winning DuPont Analysis & Pick 3 Top Stocks
by Sanghamitra Saha
Do you have more faith in DuPont analysis than simple ROE calculation? Tap EverQuote (EVER), Hims & Hers Health (HIMS) and Sprouts Farmers Market (SFM).
Labcorp Stock Climbs 25.6% This Year: What's Driving the Surge?
by Zacks Equity Research
LH stock surges 25.6% this year, powered by specialty testing expansion, key acquisitions and solid financials.
DGX Stock Up on New Blood Test Development Deal With MD Anderson
by Zacks Equity Research
DGX stock rises on a new partnership with MD Anderson to develop a blood test targeting multiple cancer risks.
GEHC Stock Declines Despite Expansion in Precision Care Capabilities
by Zacks Equity Research
GE HealthCare integrates proprietary algorithms into MIM Encore to advance digital imaging and workflow precision.
QGEN Stock Rises in After Market Following Partnership With Incyte
by Zacks Equity Research
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.
Should You Hold Myriad Genetics Stock in Your Portfolio Right Now?
by Zacks Equity Research
MYGN sees growth in oncology and women's health testing, but GeneSight coverage loss clouds the near-term outlook.
Should First Trust Mid Cap Core AlphaDEX ETF (FNX) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNX
Should You Add QIAGEN Stock to Your Portfolio for Now?
by Zacks Equity Research
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hims & Hers Health (HIMS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.